Bitcoin price today: gains to $120k, near record high on U.S. regulatory cheer
P3 Health Partners Inc. (NASDAQ:PIII), a company specializing in health services, announced the approval of a reverse stock split following a Special Meeting of Stockholders. With the stock down nearly 77% over the past year and trading at $0.18, the meeting, which took place on Sunday, saw shareholders vote on two key proposals, with the reverse stock split motion receiving significant support.
The first proposal, which was to approve amendments for a reverse stock split of the company’s Class A and Class V common stock, received 227,773,176 votes in favor, 9,377,137 against, and 10,925 abstentions. The approved ratio for the reverse stock split ranges from 1-for-10 to 1-for-60, to be determined at the discretion of the Board of Directors. Additionally, the Board retains the right to abandon the amendments if deemed necessary.
A second proposal, which sought approval to adjourn the Special Meeting to solicit more proxies if there weren’t enough votes to approve the first proposal at the time of the meeting, also passed. It garnered 227,648,046 votes for, 9,484,329 against, and 28,863 abstentions.
The reverse stock split is intended to be implemented at a timing and ratio to be specified by the Board, and no further approval from the company’s stockholders will be required. Details of the final ratio and the timing for the reverse stock split will be publicly announced once determined by the Board.
This strategic move comes as P3 Health Partners Inc. continues to navigate the health services industry, with the aim of optimizing its capital structure. According to InvestingPro data, the company faces significant financial challenges, including a debt-to-equity ratio of 2.19 and negative EBITDA of $232.7 million in the last twelve months. The company, which was formerly known as Foresight Acquisition Corp., has its principal executive offices located in Henderson, Nevada.
The information detailed in this article is based on a press release statement from P3 Health Partners Inc. and reflects the latest significant corporate action by the company as filed with the Securities and Exchange Commission. InvestingPro analysis suggests the stock may be undervalued at current levels, with additional insights available through their comprehensive Pro Research Report, which provides detailed analysis of over 1,400 US stocks, including PIII’s financial health score of FAIR.
In other recent news, P3 Health Partners Inc. reported its fourth-quarter 2024 financial results, revealing a revenue of $370.7 million, which marked a 7% year-over-year increase but fell short of analyst expectations of $378 million. The company also disclosed an adjusted EBITDA loss of $67.6 million, significantly wider than the anticipated losses of $28 million. Additionally, P3 Health Partners reported an adjusted loss per share of $0.36, which was notably below the forecasted loss of $0.19. Despite these financial challenges, the company reaffirmed its guidance for 2025, maintaining revenue projections between $1.35 billion and $1.5 billion and an adjusted EBITDA range of a $35 million loss to a $5 million gain.
BTIG reiterated a Neutral rating on P3 Health Partners following these results, highlighting concerns about the company’s financial performance and the competitive nature of the Medicare Advantage space. The firm expressed caution, noting the need for substantial positive EBITDA and cash flow before a more favorable outlook could be considered. P3 Health Partners pointed out that approximately $29 million in one-time costs, related to accounting procedure rectifications, impacted the quarter’s financials. The company remains optimistic about achieving profitability in 2025, driven by strategic initiatives and improvements in the Medicare sector.
The healthcare provider also emphasized its focus on improving operational efficiencies, which are expected to contribute to an incremental EBITDA benefit of over $130 million. Despite the earnings miss, P3 Health Partners expressed confidence in its strategic direction, highlighting a slight increase in membership guidance and ongoing improvements in utilization trends. The company also reported a cash balance of $38.8 million as of December 31, 2024, with additional revenue received in early 2025 to support its operations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.